Cagrilintide combined with semaglutide (CagriSema) for treatment of type 2 diabetes In a recent small phase 2 trial (n=92), 3 groups of patients with type 2 diabetes were randomized to receive cagrilintide co-administered with semaglutide (the authors called this combination CagriSema), cagrilintide or semaglutide, both in doses escalated to 2.4 mg once weekly (table 1) [10]
to deep hydration and barrier reinforcement
For gut barrier support specifically, consider a supplement featuring Akkermansia muciniphila alongside a broader multi-strain probiotic
Anticancer Drugs , 8 , 345348
Repair proceeds through overlapping phases: hemostasis, inflammation, proliferation (angiogenesis, fibroplasia, matrix deposition), and remodeling (maturation and cross-linking of the matrix)
Both studies were conducted in accordance with Good Clinical Practice, the Declaration of Helsinki and US Food and Drug Administration/European Medicines Agency guidelines for studies in people with renal or hepatic impairment [12,13,14,15]